Identification of retinoids with nuclear receptor subtype-selective activities
Related Experiment Videos
J M Lehmann1, M I Dawson, P D Hobbs
1Cancer Center, La Jolla Cancer Research Foundation, California 92037.
Abstract:
Retinoic acid (RA) and its synthetic analogues, retinoids, have shown promising results in the prevention of epithelial carcinogenesis and in the treatment of acute promyelocytic leukemia and various proliferative skin disorders. Retinoid action on gene regulation is mediated by three distinct nuclear retinoic acid receptor subtypes, RA receptors alpha, beta, and gamma. The existence of multiple RA receptors has raised the possibility that receptor subtype-specific retinoids with reduced side effects can be developed. To analyze the activity of retinoids at the molecular level, we used a receptor activation assay. RA and 22 retinoids were compared on the three receptor subtypes. We found the alpha receptor to be least sensitive to activation by RA and the gamma receptor to be most sensitive. Compared with RA, one of the retinoids showed increased activity for the alpha and beta receptors. Three retinoids revealed no gene activation activity and showed no antagonistic effects when assayed in the presence of RA. Surprisingly, several of the retinoids were efficient activators of the beta and gamma receptors but poor activators or nonactivators of the alpha receptor. Our data demonstrate that the three RA receptor subtypes have differential ligand activation specificities and that the design of receptor subtype-selective retinoids is possible.
Insights
Retinoids, used to treat cancers and skin disorders, act via retinoic acid receptors (RARs). This study found that different retinoids activate RAR-alpha, -beta, and -gamma receptors with varying specificities, enabling targeted drug design.
Area of Science:
- Molecular biology
- Pharmacology
- Cancer research
Background:
- Retinoic acid (RA) and its synthetic analogs, retinoids, are vital in treating epithelial cancers and skin disorders.
- RA's effects are mediated by three nuclear receptor subtypes: RAR-alpha, RAR-beta, and RAR-gamma.
- Developing subtype-specific retinoids could reduce side effects and improve therapeutic outcomes.
Purpose of the Study:
- To investigate the molecular-level activity of various retinoids on the three nuclear retinoic acid receptor subtypes.
- To determine if receptor subtype-selective retinoids can be designed based on differential ligand activation specificities.
Main Methods:
- A receptor activation assay was employed to compare the activity of RA and 22 synthetic retinoids.
- The binding and activation affinities of each retinoid were tested across RAR-alpha, RAR-beta, and RAR-gamma subtypes.
Main Results:
- RAR-gamma was most sensitive to RA activation, while RAR-alpha was least sensitive.
- Some retinoids demonstrated increased activity on RAR-alpha and RAR-beta compared to RA.
- Several retinoids selectively activated RAR-beta and RAR-gamma, showing minimal or no activity on RAR-alpha.
Conclusions:
- The three retinoic acid receptor subtypes exhibit distinct ligand activation specificities.
- These findings confirm the feasibility of designing receptor subtype-selective retinoids.
- Targeted retinoid therapies with potentially reduced side effects are achievable.